The interface between pharmacoepidemiology and pharmacogenetics

European Journal of Pharmacology

Volumn 410, Issue 2-3, 2000, Pages 121-130

  Maitland Van der Zee, Anke Hilse ^a   De Boer, Anthonius ^a   Leufkens, Hubertus G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Pharmacoepidemiology; Pharmacogenetics; Pharmacotherapy; Polymorphism

Indexed keywords

DRUG;

ARTICLE; DRUG EFFECT; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL;

ANIMALS; HUMANS; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 0034723035     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00810-4     Document Type: Article

References (53)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Toward an integrated approach to molecular epidemiology
3. Non-functional CYP2D6 alleles and the risk for neuroleptic-induced movement disorders in schizophrenic patients
4. Pharmacogenetic prediction of clozapine response
5. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma
6. Pharmacogenomics - It's not just pharmacogenetics
7. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
8. The haemolytic effect of various regiments of primaquine with chloroquine in American Negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism
9. Viewpoint - Pharmacogenetics and its impact on drug development
10. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs
11. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension
12. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes
13. Pharmacogenomics: Translating functional genomics into rational therapeutics
14. Pharmacogenomics: A new approach to individual therapy of hypertension?
15. Effect of genetic differences in omeprazole metabolism on cure rater for Helicobacter pylori infection and peptic ulcer
16. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype
17. How will knowledge of the human genome affect drug therapy?
18. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma
19. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition
20. One's grandparents as the determinant of effective antihypertensive therapy
21. The future of molecular epidemiology
22. Association study of transforming growth factor alpha (TGFα) TaqI polymorphisms and oral clefts: Indication of gene-environment interaction in a population-based sample of infants with birth defects
23. Does the angiotensin converting enzyme gene polymorphism affect patients response to ACE inhibitors?
24. Genetic epidemiology
25. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls!
26. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors
27. Genetic variation as a guide to drug development
28. 3:5:13:14 and type 2 diabetes mellitus: An association in American Indians with genetic admixture
29. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
30. Variability in patterns of drug usage
31. Pharmacogenomics: The promise of personalized medicine
32. The use of single-nucleotide polymorphism maps in pharmacogenomics
33. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine
34. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
35. The ACE gene polymorphism: The good, the bad and the ugly
36. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
37. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
38. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients
39. Pharmacogenetics and future drug development and delivery
40. Genomic medicine and the future of health care
41. Relationship between angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies
42. Potential misinterpretation of the case-only study to assess gene-environment interaction
43. G-protein β3 subunit 825T allele and response to dietary salt in normotensive men
44. Genomics raising disease redefinition, other orphan issues
45. Estrogen use and early onset Alzheimer's disease: A population-based study
46. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
47. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
48. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
49. Therapeutic lessons from pharmacogenetics
50. 3:5:13:14 and stated-admixture in American Indians